Search

News Are SGLT2 Inhibitors Only Suitable for the Treatment of Diabetes?

SGLT2 inhibitors, or gliflozins, are effective antidiabetic drugs that have shown nephroprotective and cardioprotective effects in diabetics, repeatedly demonstrated in clinical trials. At the European Cardiology Congress in September 2019 in Paris, results were presented from the DAPA-HF study, where dapagliflozin became the first SGLT2 inhibitor to show benefits in patients with heart failure with reduced ejection fraction of the left ventricle, regardless of whether they had type 2 diabetes or not. The study thus offered a completely new perspective on the treatment of heart failure.

Source: Modern Treatment of Diabetes 19. 2. 2020

News How trends in sports evolve among hemophiliacs and to what extent they are limited by their disease

Historically, physical activity was generally not recommended for hemophiliacs; however, with evolving treatment options and prophylaxis as the gold standard of care for these patients, sports have become part of their lives in recent years. The Netherlands, traditionally supportive of sports, including for patients with chronic illnesses, presented the results of a survey on hemophilia and sports in a poster presentation at the 13th annual EAHAD congress in The Hague this February.

Source: Quality Life Even with Hemophilia 14. 2. 2020

News Does the Risk of Recurrence of Differentiated Thyroid Carcinoma Differ by Gender?

Differentiated thyroid carcinomas (DTC) are typically diagnosed at more advanced stages in men than in women, and mortality from this disease is higher among men than women. However, it was not entirely clear whether the risk of DTC recurrence is influenced by the patient's gender independently of the disease stage at the time of diagnosis. The aim of the Canadian authors' study was to assess whether male gender is an independent risk factor for DTC recurrence.

Source: Thyroid Disorders 14. 2. 2020

News ERS 2022: What Insights Do Studies Focused on COPD Biomarkers Bring?

In this year's scientific program of the international congress of the European Respiratory Society (ERS 2022), there was also a lot of talk about the investigation of biomarkers of chronic obstructive pulmonary disease (COPD) and its acute exacerbations (COPD AE). This topic was also well-represented in the e-poster presentations section. From that section, we select 3 studies whose conclusions are summarized below.

Source: Cough Therapy 1. 11. 2022

News Does Emicizumab Change Routine Clinical Practice?

With the increasing number of patients with hemophilia A being treated with emicizumab, the question arises whether its use in any way changes established clinical practice. A team of American authors sought answers based on a survey conducted among the treating physicians of these patients. The findings were presented at the 13th Annual EAHAD Congress, which took place at the beginning of February in The Hague, Netherlands.

Source: Quality Life Even with Hemophilia 11. 2. 2020

News Nonacog Beta Pegol (N9-GP) in Bleeding Prophylaxis in Patients with Hemophilia B –⁠ Real World Data

The goal of hemophilia B treatment is currently the prevention of bleeding by administering a coagulation factor IX concentrate. The study presented below brings recent real-world data on treatment outcomes when switching to the latest preparation, nonacog beta pegol (N9-GP).

Source: Hemophilia with Movement 13. 6. 2023

News HVD 2023: Cervical Cancer May Be the First Eliminated Malignancy. What Paths Will Lead to This Goal in the Czech Republic?

Cervical cancer is the 3rd most common cancer among women aged 15–44. Annually, it is diagnosed in 750–800 women in our country, and every 29 hours, one woman dies from it in the Czech Republic. However, it could become the first oncological disease that can be eliminated. How to achieve this was discussed by the chairman of the Czech Vaccinological Society ČLS JEP and Dean of the Faculty of Military Medicine at the University of Defense in Hradec Králové, Prof. MUDr. Roman Chlíbek, Ph.D., at a symposium supported by MSD during the October XVIII. Hradec Vaccinology Days (HVD).

Source: Regular Vaccination 15. 11. 2023

News Efficacy and Safety of Etanercept in the Therapy of Arthritis

A review by experts from Genoa, Italy, focused on the available knowledge regarding the efficacy and safety of etanercept in the treatment of inflammatory rheumatic diseases.

Source: Arthritis 7. 6. 2022

News Fixed Combination of Trastuzumab and Pertuzumab for Subcutaneous Administration in Patients with Early Breast Cancer

At a symposium focused on breast cancer, held in December 2019 in San Antonio, Texas, preliminary results of the FeDeriCa clinical study were presented –⁠ comparing the pharmacokinetics, efficacy, and safety of a fixed combination of trastuzumab and pertuzumab for subcutaneous administration versus intravenous administration in patients with early-stage HER2-positive breast cancer. Based on the presented results, the drug received approval from the U.S. Food and Drug Administration (FDA).

Source: Breast Carcinoma 25. 10. 2020

News Emicizumab Changes the Lifestyle of Patients with Hemophilia A

At the World Federation of Hemophilia (WFH) meeting, data were presented regarding the impact of emicizumab on the lifestyle of people with hemophilia A.

Source: Quality Life Even with Hemophilia 30. 9. 2020

News Cost-effectiveness in Bleeding Control for Acquired Hemophilia A

A pharmacoeconomic analysis showed favorable cost-effectiveness of activated prothrombin complex concentrate in the indication of bleeding control in patients with acquired hemophilia A.

Source: Hemophilia 18. 9. 2020

News Final Analysis of the STASEY Study: How Did Emicizumab Perform in Prophylaxis of Hemophilia A Patients with FVIII Inhibitors?

The July virtual congress of the International Society on Thrombosis and Haemostasis (ISTH) 2021 offered a range of interesting topics. In its poster section, data from the multicenter single-arm open-label phase III clinical trial STASEY, which evaluated the safety and tolerance of emicizumab prophylaxis in patients with hemophilia A and an inhibitor of coagulation factor VIII (FVIII), were presented. Víctor Jiménez-Yuste from La Paz University Hospital in Madrid presented the study results on behalf of the international team of authors.

Source: Quality Life Even with Hemophilia 29. 11. 2021

News Impact of Empagliflozin on the Risk of Cardiovascular Death and Need for Hospitalization Due to Heart Failure

In the EMPA-REG OUTCOME study, empagliflozin reduced the risk of cardiovascular death and the number of hospitalizations due to heart failure in patients with type 2 diabetes (T2DM) who had confirmed cardiovascular disease at study entry. In the following analysis, the authors focused on the benefit of empagliflozin in patients with different levels of risk for heart failure development.

Source: Diabetes 10. 4. 2020

News Trifluridine/tipiracil, regorafenib, or supportive therapy? Factors affecting the success of mCRC treatment

Currently, there are no biomarkers available to help decide, for a specific patient with refractory metastatic colorectal cancer (mCRC), whether therapy with trifluridine/tipiracil or regorafenib will be more effective and which patients will benefit the most from the treatment. A group of Czech oncologists presented the results of their analysis on this topic at the Gastrointestinal Symposium of the American Society of Clinical Oncology (ASCO) held in January 2020 in San Francisco.

Source: Treatment of Gastrointestinal Carcinomas 15. 9. 2020

News Reflection of Progress in Hemophilia Treatment in Current WFH Recommendations

In June 2020, the new, third guidelines of the World Federation of Hemophilia (WFH) were introduced. They are based on the fact that in the past 5 years there has been significant progress in the management of hemophilia, mainly due to the introduction of new −⁠ even revolutionary −⁠ drugs into clinical practice.

Source: Quality Life Even with Hemophilia 30. 9. 2020